Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Radiochemotherapy in Anal Cancer (ACCORD 16)
NCT00955240Phase 2Terminated
- Sponsor
- Unicancer
- Start
- Mar 2009
- Primary completion
- Nov 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in anal cancer, sponsored by Unicancer. Primary endpoint: Objective response (complete and partial). Started Mar 2009; status: terminated.
02
Drugs
cetuximab
03
Conditions
anal cancer
Beyond the preview
Go deeper on NCT00955240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00955240.